Novo Nordisk receives Investment Bank Analyst Rating Update
COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk (CSE:NOVOb) said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in...
By Peter Nurse Investing.com - European stock markets were mixed in muted trade Tuesday, as investors warily assessed the likely impact on global growth from the surge in COVID...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
Despite Wall Street’s ongoing bearish sentiment, new exchange-traded funds (ETF) have continued to reach the market in impressive numbers in 2022. ETFs listed in the US...
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
|Average||931.67 (+641.13% Upside)|
|No. of Analysts||5|